查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
胃癌治療市場 - 全球行業規模、份額、趨勢、機會和預測，2018-2028 年：按治療類型、癌症類型、給藥途徑、治療類別、分銷渠道、地理細分、競爭
市場調查報告書
商品編碼
1255250

胃癌治療市場 - 全球行業規模、份額、趨勢、機會和預測，2018-2028 年：按治療類型、癌症類型、給藥途徑、治療類別、分銷渠道、地理細分、競爭

Stomach Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Treatment Type, By Cancer Type, By Route of Administration, By Drug Class, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球胃癌治療市場預計在預測期內將出現顯著增長。

這是由於治療胃癌的新藥和治療方法的開發取得了進展。 此外，對較少痛苦和低成本治療的需求增加以及癌症治療的有利報銷方案正在顯著推動世界各地胃癌治療的增長。 此外，預計到 2028 年，容易患胃癌等慢性病的老齡化社會的到來將增加對各種癌症治療的需求，並加速市場增長。 此外，在預測期內，人們對新療法益處的認識不斷提高，全球癌症疾病支出的增加預計將進一步支持胃癌治療市場。

胃癌患病率增加

全球範圍內腺癌、淋巴瘤和胃腸道間質瘤發病率的增加推動了預測期內的市場增長。 同樣，日益老齡化的人口，尤其是老年男性，更容易患胃癌等慢性病，胃癌是世界上最常見的致命癌症之一。 預計這將在預測期內推動市場增長。 據美國國家癌症研究所估計，2022 年美國將有 26,380 例胃癌新發病例，並有 11,090 例死亡。 在新興國家，男性比女性更容易被診斷出胃癌，因為女性的細胞中有某些保護基因的額外拷貝，而男性則沒有。 該地區胃癌患病率不斷上升，需要有效的治療方法來治療患者，預計這將在預測期內推動市場增長。 例如，根據加拿大癌症協會公佈的2021年統計數據，有4000名加拿大人患有胃癌。

醫療保健行業的崛起

由於政府對新開發藥物的批准增加以及胃癌患病率的增加，預計胃癌市場將在多年內創造有利可圖的增長前景。 研發活動在新藥和治療的開發中發揮著重要作用。 例如，台灣的一個研究團隊最近發表了兩種胃癌生物標誌物。 這一進步可以為胃癌市場帶來顯著的增長前景，並推動市場增長。 同樣，口服藥物也有望在預測期內促進市場增長，因為大多數產品都是膠囊或片劑，這使它們成為非常可行的給藥途徑。 公眾健康意識的提高有望推動胃癌治療市場的增長。 胃癌治療創新療法的推出有望同時加強市場。 各種研究人員和政府機構正在投資開發不僅有利於患者而且有利於市場的新藥，這在市場上創造了更多機會。 據估計，到 2022 年，美國將有 11,090 人死於這種疾病（6,690 名男性和 4,400 名女性）。 到 2020 年，全球估計有 768,793 人死於胃癌。

近期發展

例如，2021年4月，美國FDA批准Bristol-Myers Squibb K.K.產品Opdivo與氟嘧啶和含鉑化療聯合用於治療轉移性胃癌。

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第五章胃癌藥物全球市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按治療類型（免疫療法、靶向療法、化學療法、放射療法、其他）
    • 按癌症類型（胃癌/胃食管交界處癌/胃腸道間質瘤）
    • 通過給藥途徑（口服/注射）
    • 按藥物類別（PD-1/PD-L1 抑製劑、HER2 拮抗劑、VEGFR2 拮抗劑等）
    • 按分銷渠道（醫院藥房、專業藥房、其他）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 按治療類型
    • 按癌症類型
    • 按給藥途徑
    • 按治療類別
    • 按分銷渠道
    • 按地區

第六章北美胃癌治療市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按治療類型
    • 按癌症類型
    • 按給藥途徑
    • 按治療類別
    • 按分銷渠道
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 加拿大
    • 墨西哥

第七章歐洲胃癌治療市場前景

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按治療類型
    • 按癌症類型
    • 按給藥途徑
    • 按治療類別
    • 按分銷渠道
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第八章亞太胃癌治療市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按治療類型
    • 按癌症類型
    • 按給藥途徑
    • 按治療類別
    • 按分銷渠道
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第9章南美洲胃癌治療市場前景

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按治療類型
    • 按癌症類型
    • 按給藥途徑
    • 按治療類別
    • 按分銷渠道
    • 按國家
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章中東和非洲的胃癌治療市場前景

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按治療類型
    • 按癌症類型
    • 按給藥途徑
    • 按治療類別
    • 按分銷渠道
    • 按國家
  • MEA：國家分析
    • 南非胃癌治療
    • 沙特阿拉伯的胃癌治療
    • 阿聯酋胃癌治療
    • 土耳其的胃癌治療
    • 埃及胃癌治療

第 11 章市場動態

  • 主持人
  • 任務

第12章市場趨勢與發展

  • 近期趨勢
  • 併購
  • 產品發布

第13章競爭格局

  • 業務概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT 分析
    • Pfizer, Inc.
    • Novartis International AG
    • Eli Lilly and Company
    • Bristol Myers Squibb Company
    • Teva Pharmaceutical Industries AG
    • F. Hoffmann La Roche AG
    • Mylan N.V.
    • Celltrion Healthcare Co., Ltd
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.

第 14 章戰略建議

簡介目錄
Product Code: 14348

The global stomach cancer treatment market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing development of novel drugs and therapies for treating stomach cancer. Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenarios for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe. Additionally, the growing aging population across the globe, which is more prone to different kinds of chronic diseases like stomach cancer, is further expected to increase the demand for different cancer therapies, thereby fuelling market growth through 2028. Besides, growing awareness about the benefits of new therapies, with increasing expenditure on cancer diseases worldwide, is further expected to support the stomach cancer treatment market during the forecast period.

Growing Prevalence of Stomach Cancer

Increasing incidences of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the world are driving market growth during the forecast period. Similarly, the rising aging population is susceptible to chronic diseases like stomach cancer, which is one of the most common deadly cancers worldwide, especially among older males. This is expected to boost market growth in the forecast period. According to National Cancer Institute, in 2022, 26,380 new stomach cancer cases and 11,090 deaths are estimated in the United States. In developing countries, stomach cancer is more diagnosed in males than females because females carry an extra copy of certain protective genes in their cells that men don't have. The increasing prevalence of gastric cancer in the region is demanding effective therapies for treating patients, which, in turn, is expected to propel the market growth during the forecast period. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were affected by gastric cancer.

Growing Development In Healthcare Industry

Increasing approval of newly developed drugs from the government, along with the growing prevalence of stomach cancer, is expected to create a lucrative growth prospect for the stomach cancer market over the years. Research & Development activities play a major role in developing novel drugs and therapies. For instance, a research team from Taiwan has recently launched two gastric cancer biomarkers. This advancement may bring remarkable growth prospects for the stomach cancer market, thereby boosting the market growth. Similarly, oral drugs are expected to boost market growth during the forecast period as most products are available in capsules and tablets, making it a very feasible route of administration. Growing health awareness among the population is expected to boost the stomach cancer treatment market growth. The innovative therapy launches for treating gastric cancer are expected to enhance the market simultaneously. Different researchers and government organizations are investing in the development of novel drugs that benefit the market as well as the patient; this creates more opportunities in the market. It is estimated that 11,090 deaths (6,690 men and 4,400 women) from this disease will occur in the United States in 2022. In 2020, an estimated 768,793 people died from stomach cancer worldwide.

Market Segmentation

The global stomach cancer treatment market can be segmented by treatment type, cancer type, route of administration, drug class, distribution channel, and by region. Based on treatment type, the market can be segmented into Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, and Others. Based on cancer type, the market can be differentiated into Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors. Based on the route of administration, the market can be divided into Oral v/s Injectables. Based on drug class, the market can be segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, and Others. Based on distribution channels, the market can be grouped into Hospital Pharmacies, Specialty Pharmacies, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global stomach cancer treatment market on account of the growing demand for advanced cancer therapy in the country.

Market Players

Pfizer, Inc., Novartis International AG, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries AG, F. Hoffmann La Roche AG, Mylan N.V., Celltrion Healthcare Co., Ltd, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. are some of the leading players operating in the Global Stomach Cancer Treatment Market.

Recent Developments

For instance, in April 2021, the U.S. FDA approved Bristol-Myers Squibb Company's product Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of metastatic gastric cancer.

Report Scope

In this report, global stomach cancer treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Stomach Cancer Treatment Market, By Treatment Type:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Others

Stomach Cancer Treatment Market, By Cancer Type:

  • Gastric Cancer/Gastroesophageal Junction Cancer
  • Gastrointestinal Stromal Tumors

Stomach Cancer Treatment Market, By Route of Administration:

  • Oral
  • Injectables

Stomach Cancer Treatment Market, By Drug Class:

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR2 Antagonists
  • Others

Stomach Cancer Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Others

Stomach Cancer Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Stomach Cancer Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Stomach Cancer Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others)
    • 5.2.2. By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors)
    • 5.2.3. By Route of Administration (Oral v/s Injectables)
    • 5.2.4. By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Treatment Type
    • 5.3.2. By Cancer Type
    • 5.3.3. By Route of Administration
    • 5.3.4. By Drug Class
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Stomach Cancer Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Cancer Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Drug Class
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Stomach Cancer Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Drug Class
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Stomach Cancer Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Drug Class
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Stomach Cancer Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Drug Class
        • 6.3.3.2.5. By Distribution Channel

7. Europe Stomach Cancer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Cancer Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Drug Class
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Stomach Cancer Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Drug Class
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Germany Stomach Cancer Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Drug Class
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Stomach Cancer Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Drug Class
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Stomach Cancer Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Drug Class
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Stomach Cancer Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Drug Class
        • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Stomach Cancer Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Drug Class
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Stomach Cancer Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Drug Class
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Stomach Cancer Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Drug Class
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Stomach Cancer Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Drug Class
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Stomach Cancer Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Drug Class
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Stomach Cancer Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Drug Class
        • 8.3.5.2.5. By Distribution Channel

9. South America Stomach Cancer Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Cancer Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Drug Class
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Stomach Cancer Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Drug Class
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Argentina Stomach Cancer Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Drug Class
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Colombia Stomach Cancer Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Drug Class
        • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Stomach Cancer Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Cancer Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Drug Class
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Stomach Cancer Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Drug Class
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Stomach Cancer Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Drug Class
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Stomach Cancer Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Drug Class
        • 10.3.3.2.5. By Distribution Channel
    • 10.3.4. Turkey Stomach Cancer Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment Type
        • 10.3.4.2.2. By Cancer Type
        • 10.3.4.2.3. By Route of Administration
        • 10.3.4.2.4. By Drug Class
        • 10.3.4.2.5. By Distribution Channel
    • 10.3.5. Egypt Stomach Cancer Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Treatment Type
        • 10.3.5.2.2. By Cancer Type
        • 10.3.5.2.3. By Route of Administration
        • 10.3.5.2.4. By Drug Class
        • 10.3.5.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
  • 13.6. SWOT Analysis
    • 13.6.1. Pfizer, Inc.
    • 13.6.2. Novartis International AG
    • 13.6.3. Eli Lilly and Company
    • 13.6.4. Bristol Myers Squibb Company
    • 13.6.5. Teva Pharmaceutical Industries AG
    • 13.6.6. F. Hoffmann La Roche AG
    • 13.6.7. Mylan N.V.
    • 13.6.8. Celltrion Healthcare Co., Ltd
    • 13.6.9. Merck & Co., Inc.
    • 13.6.10. Teva Pharmaceutical Industries Ltd.

14. Strategic Recommendations